key: cord-0801641-am6p8dqy
authors: Olesen, Scott W; Zaman, Amanda; Osman, Majdi; Ramakrishna, Bharat
title: Modelling donor screening strategies to reduce the risk of SARS-CoV-2 transmission via fecal microbiota transplantation
date: 2020-10-19
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofaa499
sha: 7974c0281c7ba79dc4876882e693530e9180c911
doc_id: 801641
cord_uid: am6p8dqy

The potential for transmission of SARS-CoV-2 shed in stool via fecal microbiota transplantation is not yet known, and the effectiveness of various testing strategies to prevent FMT-based transmission has also not yet been quantified. Here we use a mathematical model to simulate the utility of different testing strategies.

Fecal microbiota transplantation (FMT), the instillation of stool from a healthy donor into a patient's gut, is a recommended therapy for the most common hospital-acquired infection in the United States, Clostridioides difficile, and is being explored as an experimental therapy for dozens of other conditions. 1, 2 As with all human-derived therapies, the safety of FMT depends on screening donors to prevent transmission of pathogens via the procedure, 3 and screening guidelines must be continually updated to account for emerging pathogens. 4 SARS-CoV-2, the virus that causes COVID-19, is primarily considered a respiratory pathogen, but evidence suggests that the virus is able to independently replicate in the gut, raising the possibility of transmission via the fecal oral-route or via FMT. 5 Practitioners 5-7 and regulators 8 have therefore called for screening of FMT donors for SARS-CoV-2. However, because of the virus's long incubation period, the high proportion of infected individuals that are asymptomatic, 9 and the long period in which apparently-recovered individuals can continue to shed virus in their stool, 10-13 screening FMT donors using COVID-19 clinical assessment alone may be insufficient, and the optimal available strategy for detecting asymptomatic carriage among FMT donors is unclear. We therefore developed a mathematical model of SARS-CoV-2 infection among FMT donors that simulates the effect of testing using polymerase chain reaction (PCR) with nasopharyngeal swabs, stool-based PCR tests, donor serology tests, or a combination of those assays. The model quantifies the effect of more stringent testing on the desirable reduction in potentially infectious, virus-positive donations processed into FMT material and released for use as well as the undesirable reduction in virusnegative donations released.

A c c e p t e d M a n u s c r i p t

We built an abstract model of FMT donors, simulating their donation schedule, SARS-CoV-2 infection incidence, and COVID-19 disease course. We incorporated various screening strategies, accounting for the imperfect specificity and sensitivity of each test, to estimate how many virus-negative donations would be appropriately released for use and how many virus-positive donations would be undesirably released. A conceptual overview of the model is given here. A step-by-step algorithm is in the Supplemental Information, and example simulations are shown in Supplemental Data 1.

Parameters for the model are in Table 1 .

We simulate the course of SARS-CoV-2 infection according to the general picture of Sethuraman et al. 14 A donor is either uninfected or in 1 of 4 disease phases, summarized in Supplemental Table 1 .

Each donor has a daily probability of becoming infected. Once a donor is infected, they progress through 4 disease phases:

1. Infected I 1 . Donors in this phase have detectable virus in the nasopharynx, but do not shed virus in stool and do not have detectable IgG antibodies. They may be symptomatic. We ignore any latent period, as it is not relevant to the model: symptomatic donors display symptoms on their first day in this phase. We did not consider the role of immunity because the chance of multiple asymptomatic, undetected infections during the simulation period is low.

Simulated donors are screened for the virus according to a screening strategy that consists of one or more of 4 individual test types:

 Daily symptoms checks  Nasopharyngeal PCR swabs test performed at 14-day intervals  Blood IgG antibody tests at 60-day intervals  Stool PCR tests performed at 14-day intervals, at 28-day intervals, or at every donation In simulations, described below, we evaluated 10 screening strategies: for release only if they are "bookended" by two negative tests. 4 In other words, any donations made after the last negative test conducted before the first positive test are rejected.

The model has two outcomes: the number of "true negative", virus-negative donations released and the number of "false negative", virus-positive donations released. A desirable screening strategy will release many virus-negative donations and few or no virus-positive donations, while a poor strategy will needlessly destroy many virus-negative donations or release many virus-positive donations.

To evaluate the effectiveness of different testing strategies, 10,000 simulations were run for each of 3 incidences (1 infection per 100 people per day; 1 per 1,000; or 1 per 10,000) and each of the 10 screening strategies listed above.

To evaluate the sensitivity of the model outcomes to the input parameters, 10,000 simulations were run with varying parameters. All parameters were varied simultaneously. In each simulation, random values were drawn for each parameter from a uniform distribution whose lower and upper bounds are shown in Table 1 . Sensitivity between each input parameter and each of the 2 outcomes was assessed using Spearman's ρ correlation.

Simulations and analyses were run using R (version 3.6.0). 15 Code to reproduce the results is available online (DOI: 10.5281/zenodo.3903840).

The number of virus-positive and -negative donations released varied over simulations and depended on the incidence of infection and the testing strategy (Figure 1 , Supplemental Table 2 ). As expected, the risk that a released donation is virus-positive varied approximately proportionally with the incidence of infection: a 10-fold increase in incidence led to an approximately 10-fold increase in risk. Also as expected, the more stringent strategies released fewer virus-positive donations, but they also released fewer virus-negative donations per donor due to false positive test results (Supplemental Table 2 ). Thus, the more sensitive strategies were also less specific.

Testing strategies decreased the risk of a released donation being virus-positive by similar factors regardless of the incidence of infection (Supplemental Figure 1 , Supplemental Table 2 ). For example, whether the incidence of infection was 1 per 100 people per day or only 1 per 10,000, the odds that a released donation would be virus-positive was 48-or 127-fold lower, respectively, under the most stringent strategy (symptoms checks, nasopharyngeal swabs, serology tests, and testing every stool) compared to symptoms checks alone.

In a sensitivity analysis (Supplemental Figure 2) , the parameters most strongly associated with the two outcomes (Spearman's ρ > 10%) were SARS-CoV-2 incidence, donation interval, the specificities of the stool and swab tests, and the probability of asymptomatic infection.

A c c e p t e d M a n u s c r i p t DISCUSSION A mathematical model of SARS-CoV-2 infection among stool donors suggests that, if the parameter estimates are accurate and a stringent testing strategy is used, then the probability of releasing a virus-positive donation for clinical use is low. More stringent tests were more sensitive but also less specific, and the most appropriate strategy must be determined by a balance between the necessary stringency and logistical considerations like resourcing.

The strength of this analysis is its quantitative treatment of a pressing clinical question. However, it has multiple limitations. First, as a modeling study, the accuracy of the results depends on the accuracy of the input parameters and the appropriateness of the model structure, especially the tests' sensitivity and specificity, which remain subject to refinement, as well as the incidence of SARS-CoV-2 infection, which may differ between stool donors compared to the general population.

Thus, the quantitative predictions made by the model should be used as a guide for evaluating the costs and benefits of more stringent testing rather than as a direct calculation of the risk of FMT material being virus-positive. Second, the model makes a number of assumptions about the course of disease that may be shown to be invalid or that are no longer applicable. For example, our assumption that newly enrolled donors are seronegative maximizes the sensitivity of serology testing. As the number of candidate donors with positive serology rises, the sensitivity and utility of the serology test will decline. Finally, verifying the model would be challenging, as the possibility of fecal-oral transmission of SARS-CoV-2 has not been confirmed, and there is no accepted "gold standard" for detecting SARS-CoV-2 in stool.

Although these results are encouraging, we again caution that they depend on a number of assumptions about testing quality, available testing modalities, and SARS-CoV-2 epidemiology that will be refined in the coming months. Nevertheless, this method is valuable in assessing the risks of transmission in this evolving pandemic, and we hope this approach can serve as a model for evaluating testing strategies for other pathogens or human-derived therapies beyond FMT.

A c c e p t e d M a n u s c r i p t M a n u s c r i p t The point estimate of 10 -4 corresponds to 35,000 daily cases in a population of 350 million, approximating the US average in early April 2020. c: Informed by an assay being implemented at a large stool bank.

The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications

Global disparities in faecal microbiota transplantation research

International consensus conference on stool banking for faecal microbiota transplantation in clinical practice

Stool banking for fecal microbiota transplantation: methods and operations at a large stool bank

Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel

Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward

Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic

US Food and Drug Administration. Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Additional Safety Protections Pertaining to SARS-CoV-2 and COVID-19

The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples

Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding

Prolonged SARS-Cov-2 RNA Detection in Anal/Rectal Swabs and Stool Specimens in COVID-19 Patients After Negative Conversion in Nasopharyngeal RT-PCR Test

Interpreting Diagnostic Tests for SARS-CoV-2

R: A language and environment for statistical computing. (R Foundation for Statistical Computing

Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province

Prolonged Fecal Shedding of SARS-CoV-2 in Pediatric Patients: A Quantitative Evidence Synthesis

Do children need a longer time to shed SARS-CoV-2 in stool than adults?

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

Clinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients

False Negative Tests for SARS-CoV-2 Infection -Challenges and Implications

False-negative results of initial RT-PCR assays for COVID-19: a systematic review

Emily Langner for helpful comments.

This study did not involve patients.

The authors declare no conflicts of interest.A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Figure 1 . Proportion of released donations that are virus-positive (x-axis) in simulations at different daily incidences (insets, infections per person per day) using different testing strategies (y-axis). For a 10-fold decrease in incidence, approximately 10-fold fewer positive donations are released (N.B. different x-axis scales), but the relative ordering of the strategies remains similar. Swabs are always at 14-day intervals and serology is always at 60-day intervals. Stool tests are performed at 14-day intervals, 28-day intervals, or for every donation. All testing strategies include symptoms checks. Circles show point estimates; horizontal lines show 95% confidence intervals (binomial test). Swab, stool (14) Stool only (14) Swab, serology Swab, stool (28) Stool only (28) Swab only

Released donations that are vir us−positive (%)